Temporal Single-Cell Profiling (Live-seq)

About Cytosurge

Cytosurge is a private, commercial-stage company providing a unique technology platform and services for single-cell analysis and engineering. Its flagship FluidFM technology, originating from ETH Zurich, uses nanoscale fluidic force microscopy probes to perform cytoplasmic biopsies (Live-seq) and precise injections (e.g., for CRISPR) on living cells, enabling temporal studies of cell state transitions. The company operates a dual business model, offering both the FluidFM OMNIUM instrument for research labs and a CellEDIT service for custom cell line development, primarily targeting the cell therapy and synthetic biology markets to overcome challenges in hard-to-transfect cells and complex genetic edits.